Faeth Therapeutics, Inc. (FTH)

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company working in oncology. Its approach targets the metabolism of cancer cells, seeking to cut off the nutrients and metabolic pathways tumors depend on, including by pairing targeted drugs with precisely designed nutrition.

The company's common stock trades on the Nasdaq. Information on its pipeline, clinical programs and headquarters is available in its regulatory filings.